I have been enjoying some of the interviews you've done. Thank you very much.
I was wondering if you would ever consider interviewing Thomas Seyfried. I have read some of his work and specifically his theory about cancer being a disease of the mitochondria. As far as I can tell, he seems to focus almost exclusively on glioblastoma, which has a different metabolic phenotype than early-stage prostate cancer. I've never heard him talk about or even acknowledge this difference. It would be interesting to hear what he has to say.
If he would turn his attention to the prostate he may have some valuable insights.
Thanks
Dave
Written by
Daveofnj
To view profiles and participate in discussions please or .
I can't recall if it was Dr. Seyfried or someone else talking or writing about metabolic differences between cancers, but it was suggested that carb restriction alone might not cut it for PC, and that a metabolic approach might need to address specific amino acids (like methionine).
I know that he was in contact in recent years with a man (in Australia) who had taken a zero-ADT metabolic approach to advanced PC, with keto diet, and whose oncology team was happily surprised at the apparent benefit of slow/no PC progression. Maybe I can find an update on that case, and post.
Hi Dave I am not familiar with his work. You are welcome to direct message me if you have his contact info and I will try to follow-up. That said, you may have noticed that Malecare has produced the largest (at least, in English language) prostate cancer patient conference ever, with 48 presentations and 21 short film premiers (next week). The conference is a massive amount of work, that rests on top of my day to day work, including research and managing Malecare and several new projects we are launching in January 2021. Last year's conference had three people (including me) and 7 volunteers on the day of the conference. This conference is entirely on me. All to say, it might be a while before I get to connect with this new doctor. 🙂
Watched some of your interviews. Excellent job, great style. Are you still doing social work- clinical work? I’m also social worker, really miss the clinical work side.
Darry, Great conference, and I have learned a lot and added to my list of questions for my doctors from the presentations. It would be great if you could figure out a way to make the interviews more inclusive of the questions and concerns of the attendees. I think it is great to have you moderate and pose questions, but a broader base of questions would be a GREAT addition to these presentations. Perhaps encouraging and then adding time for the attendees' Q&As at the end of each presentation would make these stellar segments!
You pose a super idea, but one that requires a more expensive conference platform solution. I hope more people than in past years will make charitable donations this year. malecare.org/donate
Seyfried is RIGHT that cancer is metabolic...all cancers. The problem is there is no profit in the way he wants them cured, and no doctor who will proscribe the glutamine-blocking agent that cancer turns to as a last resort (after you've eliminated glucose as their food source.)
Blocking glutamine may effect cancer but at what cost? Death to the patient? How do you know pharma isn't working on treatments that block glutamine? Have you
searched the database of all pharma registered molecules, etc?
Seriously, it's the delivery systems that are equally profitable and actually most important.
The key is to direct the treatments against the targeted disease and not the healthy cells extremely difficult to do since cancer are normal cells gone rogue.
Glutamine metabolism take place in every cell in the human body hence TomTom's "death to the patient" reply.Also so far mice, mice and more mice.
Nonetheless hopefully research in this area will continue. I am sure it will and hopefully with promising applications. It's a long way off but there is no conspiracy against it. Research continues.
It has come to light that many glutamine-dependent cellular functions have gone beyond cancer cells.
In T cells, perturbation of glutamine acquisition and catabolism has a profound effect on T cell differentiation and immune response [25,69,70]. Thus, dissecting differential responses to the limitation of glutamine or glutamine-derived metabolites between tumor cells and T cells will ensure therapeutic strategies that destroy tumor growth while preserve effector and cytotoxic T cell function.
In the future, it is our anticipation that evidence will show up to fill in the gaps in our understanding of these areas. At that time, we would no longer need to worry about creating a “hungry monster” by starving cancer cells of glutamine.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
TURP for prostate cancer patients
I'd Like to Welcome Tall Allen's Recent Posts/Replies
Surgery or radiation, looking for some advices 
High cost of Xtandi - any ideas?
